Cal­adrius’ 16-year rocky his­to­ry bends again in Cend merg­er; Af­ter Cel­lec­tis, Chi­na JV pacts, Cy­tovia inks SPAC deal

Af­ter a roller coast­er span­ning 16 years, Cal­adrius Bio­sciences thinks it can re­turn to sta­ble ground in a merg­er with lit­tle-known Cend Ther­a­peu­tics.

Cal­adrius will …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER